EICHOR
● Terminated
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Condition: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma · Sponsor: Hoffmann-La Roche
About this study
A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic G/GEJ cancer (hereafter referred to as gastric cancer) and esophageal cancer. Two cohorts of patients with gastric cancer have been enrolled in parallel in this study: the second-line (2L) Gastric Cancer Cohort consists of patients with gastric cancer who have progressed after receiving a platinum-containing or fluoropyrimide-containing chemotherapy regimen in the first-line setting, and the first-line (1L) Gastric Cancer Cohort consists of patients with gastric cancer who have not received prior chemotherapy in this setting. In each cohort, eligible patients will be assigned to one of several treatment arms. Additionally, a cohort of patients with esophageal cancer who have not received prior systemic treatment for their disease will be enrolled in this study. Eligible patients will be randomized to chemotherapy or the combination of chemotherapy with checkpoint inhibitor immunotherapy.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (28)
| Mayo Clinic Cancer Center | Scottsdale, Arizona, United States | — |
| Uni of Southern California | Los Angeles, California, United States | — |
| UCLA Jonsson Comprehensive Cancer Center | Santa Monica, California, United States | — |
| Columbia University Medical Center | New York, New York, United States | — |
| Tennessee Oncology - Nashville | Nashville, Tennessee, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| Blacktown Hospital | Blacktown, New South Wales, Australia | — |
| Monash Medical Centre-Moorabbin Campus | Clayton, Victoria, Australia | — |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | — |
| Rambam Health Care Campus | Haifa, Israel | — |
| Sourasky Medical Centre | Tel Aviv, Israel | — |
| Seoul National University Bundang Hospital | Gyeonggi-do, South Korea | — |
+ 16 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03281369